Welcome to our dedicated page for Microbot Medical SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Microbot Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Microbot Medical's regulatory disclosures and financial reporting.
Microbot Medical Inc. filed a current report describing a press release about its LIBERTY® Endovascular Robotic System and recent policy from the American Medical Association on occupational radiation exposure. The AMA adopted a policy in late 2025 to strengthen protections for health care professionals and trainees exposed to ionizing radiation.
Microbot emphasizes that LIBERTY is remotely operated and, in the ACCESS-PVI Study, use of the system showed a 92% relative reduction in radiation exposure. The company began a Limited Market Release of LIBERTY in late 2025 and plans a Full Market Release at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. reported that its operations and commercial activities remain stable despite current geopolitical events in the Middle East. The company states there is no business disruption in either the U.S. or Israel, and that employee safety and security remain a top priority.
Following recent FDA clearance of its LIBERTY Endovascular Robotic System, Microbot is focusing commercialization on the U.S. market using a dedicated commercial team based in Hingham, Massachusetts. The company indicates internal operations and its lead manufacturing partner are fully functional, with sufficient U.S. inventory and additional stock being built through a third-party logistics partner.
Microbot is preparing for a full market release of the LIBERTY System at the Society of Interventional Radiology conference in April 2026, after beginning a limited market release in late 2025. To support expansion, it has hired additional U.S. sales representatives and a Director of Health Economics and Outcomes Research, while continuing to monitor Middle East developments to maintain uninterrupted customer support.
Microbot Medical Inc. reported changes to its executive employment arrangements and a one-time cash award. As of February 20, 2026, the company entered into an addendum to the employment agreement with Simon Sharon, an addendum with Rachel Vaknin, and an amendment to the employment agreement with Juan Diaz-Cartelle. On February 18, 2026, the board also authorized a special bonus of approximately $140,000 for CEO, President and Chairman Harel Gadot, which is in addition to bonuses he may receive under his existing employment agreement.
Microbot Medical reported that Tampa General Hospital has become the first health system in Florida to adopt its LIBERTY® Endovascular Robotic System, following recent FDA 510(k) clearance. The company sees this as early post-clearance momentum in a U.S. peripheral endovascular market of about 2.5 million procedures annually.
Microbot began a limited market release of LIBERTY in late 2025 and plans a full commercial launch at the Society of Interventional Radiology conference in April 2026. LIBERTY is described as a single-use, remotely operated robotic system designed to improve precision and reduce radiation exposure and physical strain during peripheral endovascular procedures.
Gadot Harel reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that Chairman, President and CEO Harel Gadot received a grant of stock options covering 480,000 shares of common stock. These options were awarded under the company’s 2020 Omnibus Performance Award Plan.
According to the grant terms, 25% of the option vests and becomes exercisable on August 18, 2026. The remaining 75% vests and becomes exercisable in equal installments on a quarterly basis over the following 30 months, subject to the plan’s provisions on possible acceleration or forfeiture.
Diaz-Cartelle Juan reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that Chief Medical Officer Juan Diaz-Cartelle received a grant of stock options covering 105,000 shares of common stock. These options were awarded at no cost as part of his compensation.
Under the company’s 2020 Omnibus Performance Award Plan, 25% of the options will vest and become exercisable on August 18, 2026. The remaining 75% will vest in equal installments on a quarterly basis over the following 30 months, subject to possible acceleration or forfeiture under the plan terms.
Sharon Simon reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that General Manager and CTO Sharon Simon was granted stock options covering 105,000 shares of common stock. According to the company’s 2020 Omnibus Performance Award Plan, 25% of the options vest and become exercisable on August 18, 2026, with the remaining 75% vesting in equal quarterly installments over the following 30 months, subject to the plan’s acceleration or forfeiture provisions.
Vaknin Rachel reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that its Chief Financial Officer, Rachel Vaknin, received a grant of stock options covering 105,000 shares of common stock. The award is a right to buy shares under the company’s 2020 Omnibus Performance Award Plan, as amended.
According to the grant terms, 25% of the options will vest and become exercisable on August 18, 2026. The remaining 75% will vest and become exercisable in equal installments on a quarterly basis over the following 30 months, subject to possible acceleration or forfeiture under the plan.
Microbot Medical Inc. filed an 8-K to share that CEO, President and Chairman Harel Gadot will be a featured panelist at The Surgical Disruptive Technology Summit during the SAGES NBT Innovation Weekend in Houston. He will join a session on endovascular therapeutics, AI and robotics.
The company uses this event to spotlight its LIBERTY Endovascular Robotic System, described as the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Microbot began a limited market release of LIBERTY in late 2025 and plans a full market release at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. filed a report describing a press release about its LIBERTY® Endovascular Robotic System being highlighted at the International Symposium on Endovascular Therapy conference in Miami Beach, Florida.
The company notes that LIBERTY, described as the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, was prominently discussed in a town hall session on advances in endovascular robotics. Management states that LIBERTY is in a limited market release that began in late 2025 and that a full market release is planned at the Society of Interventional Radiology conference in April 2026.